The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells

Purpose: Explore the regulatory function of sodium hydrosulfide (NaHS) on the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer SKOV3 cells. Methods: SKOV3 cells cultured in vitro were assigned to the control group, NaHS group, SB203580 group, and NaHS combined with SB203580 group. The effects and influences on cell proliferation were detected by MTT assay. Effects on the cell cycle and apoptosis were detected by flow cytometry. Western blot was used to detect the expression of P-p38MAPK. Results: Proliferation of SKOV3 cells were remarkably decreased in the NaHS, SB203580, and NaHS combined with SB203580 groups. Cell quantity in G1 phase and S phase increased and decreased remarkably, respectively. Obviously, cell apoptosis rate was increased in the combination group compared to single-drug treatment groups. P-p38MAPK expression in NaHS group was upregulated by comparing with that in control group, and that was markedly enhanced in the combination group compared to single-drug treatment group. Conclusions: NaHS inhibited proliferation and promoted apoptosis of SKOV3 cells by blocking the p38MAPK signaling pathway. Furthermore, coordination between NaHS and SB203580 regulated the proliferation and apoptosis of SKOV3 cells.

Human ovarian cancer cells; Sodium hydrosulfide; pP38MAPK; Cell proliferation; Cell apoptosis.

[1] Brunetti M., Holth A., Panagopoulos I., Staff A. C., Micci F. and Davidson B.: “Expression and clinical role of the dipeptidyl pepti­dases DPP8 and DPP9 in ovarian carcinoma”. Virchows Arch., 2019, 474, 177­185.

[2] Lutgendorf S. K., Division of Gynecologic Oncology, Department of Obstetrics and Gynecology; University of Iowa; Iowa City Iowa, Department of Urology; University of Iowa; Iowa City Iowa, Holden Comprehensive Cancer Center; University of Iowa; Iowa City Iowa, Thaker P. H., Arevalo J. M., et al.: “Biobehavioral modu­ lation of the exosome transcriptome in ovarian carcinoma”. Cancer, 2018, 124, 580­586.

[3] Macintyre G., Goranova T. E., De Silva D., Ennis D., Piskorz A. M., Eldridge M., et al.: “Copy number signatures and mutational processes in ovarian carcinoma”. Nat. Genet., 2018, 50, 1262­1270.

[4] Nezhat F. R., Apostol R., Nezhat C. and Pejovic T.: “New insights in the pathophysiology of ovarian cancer and implications for screen­ing and prevention”. am. J. Obstet. Gynecol., 2015, 213, 262­267.

[5] Yeung T., Leung C. S., The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas;, Yip K., Au Yeung C. L., Wong S. T. C., et al.: “Cellular and molecular pro­ cesses in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis”. American Journal of Physiology­Cell Physiology, 2015, 309, C444­C456.

[6] Li N., Center for Developmental Cardiology, Institute for Transla­ tional Medicine, College of Medicine, Qingdao University, Qingdao 266021, China, Wang M., Jin S., Department of Physiology, Hebei Medical University, Hebei 050017, China, Bai Y., et al.: “The H2S Donor NaHS Changes the Expression Pattern of H2S­Producing En­ zymes after Myocardial Infarction”. Oxid. Med. Cell. Longev., 2016, 2016, 1­11.

[7] Martelli A., Testai L., Marino A., C. Breschi M., Da Settimo F. and Calderone V.: “Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives”. Curr. Med. Chem., 2012, 19, 3325­3336.

[8] Kuksis M. and Ferguson A. V.: “Actions of a hydrogen sulfide donor (NaHS) on transient sodium, persistent sodium, and voltage­gated calcium currents in neurons of the subfornical organ”. J. Neu­ rophysiol., 2015, 114, 1641­1651.

[9] Wu W., Hou C., Mu X., Sun C., Zhu Y., Wang M., et al.: “H2S Donor NaHS Changes the Production of Endogenous H2S and NO in D­ Galactose­Induced Accelerated Ageing”. Oxid. Med. Cell. Longev., 2017, 2017, 1­14.

[10] Untereiner A. A., Oláh G., Módis K., Hellmich M. R. and Szabo C.: “H 2 S­induced S ­sulfhydration of lactate dehydrogenase a (LDHA) stimulates cellular bioenergetics in HCT116 colon cancer cells”. Biochem. Pharmacol., 2017, 136, 86­98.

[11] Untereiner A. A., Pavlidou A., Druzhyna N., Papapetropoulos A., Hellmich M. R. and Szabo C.: “Drug resistance induces the upregulation of H2S­producing enzymes in HCT116 colon cancer cells”. Biochem. Pharmacol., 2018, 149, 174­185.

[12] Breza J., Soltysova A., Hudecova S., Penesova A., Szadvari I., Bab­ ula P., et al.: “Endogenous H2S producing enzymes are involved in apoptosis induction in clear cell renal cell carcinoma”. Bmc Cancer, 2018, 18. [13] Nokkaew N., Mongkolpathumrat P., Junsiri R., Jin­ daluang S., Tualamun N., Manphatthanakan N., et al.: “p38 MAPK Inhibitor (SB203580) and Metformin Reduces Aortic Protein Car­ bonyl and Inflammation in Non­obese Type 2 Diabetic Rats”. Ind J Clin Biochem., 2019, 6. [14] Xiao Y., Yan W., Cao Y., Yan J. and Cai W.: “P38 MAPK Pharmacological Inhibitor SB203580 Alle­ viates Total Parenteral Nutrition­Induced Loss of Intestinal Barrier Function but Promotes Hepatocyte Lipoapoptosis”. Cell. Physiol. Biochem., 2017, 41, 623­634.

[13] Düzgün Ȧ., Yerlikaya A., Zeren S., Bayhan Z., Okur E. and Boy­ acı :̇ “Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA­MB­231 cancer cell line”. Cytotechnology, 2017, 69, 711­724.

[14] Rasheduzzaman M., Biosafety Research Institute, Department of Veterinary Medicine, College of Veterinary MedicineChonbuk Na­ tional University Iksan Jeonbuk South Korea, Yin H. and Park S.: “Cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation”. Mol. Carcinog., 2019, 58, 2040­2051.

[15] Guo Y., Jiang M., Zhao X., Gu M., Wang Z., Xu S., et al.: “Cy­ clophilin A promotes non­small cell lung cancer metastasis via p38 MAPK”. Thoracic Cancer, 2018, 9, 120­128.

[16] Yang J., Zhang J., Chen W., Wang G., Mao Q., Li S., et al.: “Effects of AQP5 gene silencing on proliferation, migration and apoptosis of human glioma cells through regulating EGFRERK p38 MAPK signaling pathway”. Oncotarget, 2017, 8, 38444­38455.

[17] Coleman R. L., Oza A. M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J. I., Clamp A., Scambia G., et al.: “Rucaparib maintenance treatment for recurrent ovarian carci­ noma after response to platinum therapy (ARIEL3): a randomised, double­blind, placebo­controlled, phase 3 trial”. Lancet (London, England), 2018, 3901949­1961.

[18] Menderes G., Bonazzoli E., Bellone S., Black J. D., Lopez S., Pet­tinella F., et al.: “Efficacy of neratinib in the treatment of HER2neu­ amplified epithelial ovarian carcinoma in vitro and in vivo”. Med. Oncol., 2017, 34. [21] Mendivil A. A., Rettenmaier M. A., Abaid L. N., Brown J. V., Mori K. M., Lopez K. L., et al.: “Consolida­tion hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience”. Cancer Chemother. Pharmacol., 2017, 80, 405­410.

[19] Marchan R., Büttner B., Lambert J., Edlund K., Glaeser I., Blaszkewicz M., et al.: “Glycerol­3­phosphate Acyltransferase 1 Promotes Tumor Cell Migration and Poor Survival in Ovarian Car­cinoma”. Cancer Res., 2017, 77, 4589­4601.

[20] Wu W., Hou C., Mu X., Sun C., Zhu Y., Wang M., et al.: “H2S Donor NaHS Changes the Production of Endogenous H2S and NO in D­ Galactose­Induced Accelerated Ageing”. Oxid. Med. Cell. Longev., 2017, 2017, 1­14.

[21] Sanokawa­Akakura R., Ostrakhovitch E. A., Akakura S., Goodwin S. and Tabibzadeh S.: “A H2S­Nampt Dependent Energetic Circuit Is Critical to Survival and Cytoprotection from Damage in Cancer Cells”. Plos one, 2014, 9, e108537.

[22] Han S. J., Kim J. I., Park J. and Park K. M.: “Hydrogen sulfide accel­ erates the recovery of kidney tubules after renal ischemiareperfusion injury”. Nephrology Dialysis Transplantation, 2015, 30, 1497­1506.

[23] Yan S., Chang T., Wang H., Wu L., Wang R. and Meng Q. H.: “Ef­ fects of hydrogen sulfide on homocysteine­induced oxidative stress in vascular smooth muscle cells”. Biochem. Biophys. Res. Commun., 2006, 351, 485­491.

[24] Abrahamsen H., Stenmark H. and Platta H. W.: “Ubiquitination and phosphorylation of Beclin 1 and its binding partners: Tuning class III phosphatidylinositol 3­kinase activity and tumor suppression”. Febs Lett., 2012, 586, 1584­1591.

[25] Chen Y., Shou K., Gong C., Yang H., Yang Y. and Bao T.: “Anti­ Inflammatory Effect of Geniposide on Osteoarthritis by Suppressing the Activation of p38 MAPK Signaling Pathway”. Biomed Research International, 2018, 2018, 1­11.

[26] Xu A., Shi G., Liu F. and Ge B.: “Caenorhabditis elegans mom­4 is required for the activation of the p38 MAPK signaling pathway in the response to Pseudomonas aeruginosa infection”. Protein & Cell, 2013, 4, 53­61.

[27] Zhao J., Peng W., Ran Y., Ge H., Zhang C., Zou H., et al.: “Dys­ regulated expression of ACTN4 contributes to endothelial cell in­jury via the activation of the p38­MAPKp53 apoptosis pathway in preeclampsia”. J. Physiol. Biochem., 2019, 75, 475­487.

[28] Keuling A. M., Andrew S. E. and Tron V. A.: “Inhibition of p38 MAPK enhances ABT­737­induced cell death in melanoma cell lines: novel regulation of PUMA”. Pigment Cell & Melanoma Re­ search, 2010, 23, 430­440.